丸美生物
(603983)
| 流通市值：132.29亿 | | | 总市值：132.29亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,358,091,398.2 | 1,121,728,940.78 | 1,052,582,653.57 | 1,076,726,192.77 |
| 应收票据及应收账款 | 63,431,126.49 | 79,378,003.72 | 33,400,897.54 | 31,496,325.3 |
| 其中：应收票据 | - | 820,000 | 820,000 | 3,490,000 |
| 应收账款 | 63,431,126.49 | 78,558,003.72 | 32,580,897.54 | 28,006,325.3 |
| 预付款项 | 89,060,615.42 | 43,156,158.12 | 54,315,024.36 | 24,721,206.06 |
| 其他应收款合计 | 13,140,821.53 | 12,547,194.73 | 16,614,243.45 | 14,642,022.22 |
| 存货 | 191,293,771.02 | 177,403,003.77 | 172,956,838.15 | 171,728,161.73 |
| 一年内到期的非流动资产 | 248,131,410.94 | 246,118,123.28 | 244,126,719.16 | 279,644,140.63 |
| 其他流动资产 | 141,095,202.77 | 149,274,763.14 | 161,705,830.21 | 163,023,869.33 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,596,435,890.88 | 2,321,516,986.33 | 2,442,888,855.67 | 2,529,958,082.2 |
| 非流动资产: | | | | |
| 长期股权投资 | 60,500,550.56 | 60,501,330.16 | 63,606,564.63 | 63,605,503.57 |
| 投资性房地产 | 3,356,689.29 | 3,435,127.57 | 3,513,565.85 | 3,592,004.13 |
| 固定资产 | 451,879,506.32 | 447,849,778.27 | 450,032,551.45 | 453,968,186.02 |
| 在建工程 | 494,168,371.12 | 435,610,758.65 | 349,467,010.65 | 309,481,170.75 |
| 使用权资产 | 3,213,397.63 | 4,444,547.97 | 5,464,590.6 | 6,456,803.42 |
| 无形资产 | 705,003,763.3 | 709,738,134.82 | 714,974,028.56 | 719,584,554.09 |
| 长期待摊费用 | 1,962,823.13 | 2,457,933.34 | 2,679,458.31 | 3,174,568.51 |
| 递延所得税资产 | 61,703,374.36 | 60,353,362.51 | 64,931,341.11 | 59,104,498.05 |
| 其他非流动资产 | 56,784,325.05 | 267,234,443.88 | 264,331,941.85 | 304,821,399.74 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,838,572,800.76 | 1,991,625,417.17 | 1,919,001,053.01 | 1,923,788,688.28 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,435,008,691.64 | 4,313,142,403.5 | 4,361,889,908.68 | 4,453,746,770.48 |
| 流动负债: | | | | |
| 短期借款 | 248,783,750 | 248,323,750 | 150,104,166.67 | 100,072,222.22 |
| 应付票据及应付账款 | 353,423,620.59 | 271,874,208.55 | 237,676,574.56 | 262,581,364.32 |
| 其中：应付票据 | 130,000,000 | - | - | - |
| 应付账款 | 223,423,620.59 | 271,874,208.55 | 237,676,574.56 | 262,581,364.32 |
| 合同负债 | 197,375,032.18 | 193,823,635.84 | 194,903,363.31 | 240,402,354.59 |
| 应付职工薪酬 | 14,767,540.77 | 16,189,615.39 | 14,776,591.84 | 26,992,838.64 |
| 应交税费 | 36,124,467.91 | 37,728,311.11 | 50,220,583.85 | 34,818,523.67 |
| 其他应付款合计 | 101,010,947.81 | 121,101,024.57 | 142,049,339.74 | 173,192,801.44 |
| 应付股利 | - | - | - | 1,286,387.22 |
| 一年内到期的非流动负债 | 2,124,498.5 | 2,322,812.98 | 2,708,050.75 | 152,156,347.8 |
| 其他流动负债 | 15,945,898.06 | 14,698,910.68 | 15,045,669.77 | 19,981,910.86 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 969,555,755.82 | 906,062,269.12 | 807,484,340.49 | 1,010,198,363.54 |
| 非流动负债: | | | | |
| 租赁负债 | 2,257,408.65 | 2,755,238.53 | 3,558,101.35 | 3,250,343.23 |
| 预计负债 | 360,000 | 360,000 | 360,000 | 360,000 |
| 递延收益 | 4,347,595.61 | 5,127,417.68 | 5,423,633.18 | 6,163,885.77 |
| 递延所得税负债 | 14,781,306.55 | 16,892,106.53 | 15,916,420.75 | 15,228,422.71 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 21,746,310.81 | 25,134,762.74 | 25,258,155.28 | 25,002,651.71 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 991,302,066.63 | 931,197,031.86 | 832,742,495.77 | 1,035,201,015.25 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 401,000,000 | 401,000,000 | 401,000,000 | 401,000,000 |
| 资本公积 | 760,454,706.74 | 760,454,706.74 | 760,454,706.74 | 760,454,706.74 |
| 其他综合收益 | -1,637,487.47 | -1,596,288.98 | -1,606,805.66 | -1,584,167.69 |
| 盈余公积 | 200,909,800 | 200,909,800 | 200,909,800 | 200,909,800 |
| 未分配利润 | 2,016,632,761.2 | 1,954,366,586.31 | 2,096,978,280.96 | 1,986,349,499.53 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,377,359,780.47 | 3,315,134,804.07 | 3,457,735,982.04 | 3,347,129,838.58 |
| 少数股东权益 | 66,346,844.54 | 66,810,567.57 | 71,411,430.87 | 71,415,916.65 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,443,706,625.01 | 3,381,945,371.64 | 3,529,147,412.91 | 3,418,545,755.23 |
| 负债和股东权益合计 | 4,435,008,691.64 | 4,313,142,403.5 | 4,361,889,908.68 | 4,453,746,770.48 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |